Scarica l'app Stockscreener
6.34
5.37%
-0.36
Precedente Chiudi:
$6.70
Aprire:
$6.68
Volume 24 ore:
3.93M
Relative Volume:
0.63
Capitalizzazione di mercato:
$2.21B
Reddito:
$143.05M
Utile/perdita netta:
$-145.99M
Rapporto P/E:
-14.81
EPS:
-0.4282
Flusso di cassa netto:
$-134.06M
1 W Prestazione:
-1.25%
1M Prestazione:
+11.62%
6M Prestazione:
+20.99%
1 anno Prestazione:
+168.64%
Intervallo 1D:
$6.295
$6.69
Intervallo di 1 settimana:
$6.295
$6.795
Portata 52W:
$2.18
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Nome
Nuvation Bio Inc
Settore
Industria
Telefono
332-208-6102
Indirizzo
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
6.34 | 2.32B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-19 | Iniziato | B. Riley Securities | Buy |
| 2025-09-30 | Iniziato | Jefferies | Buy |
| 2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-26 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2021-03-08 | Iniziato | BTIG Research | Buy |
| 2021-03-08 | Iniziato | Cowen | Outperform |
| 2021-03-08 | Iniziato | Jefferies | Buy |
| 2021-03-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Nuvation Bio Inc Borsa (NUVB) Ultime notizie
Nuvation Bio Inc (NUVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvation Bio Inc (NUVB) Institutional Confidence - TradingKey
Nuvation Bio Inc (NUVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvation Bio Inc (NUVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvation Bio Inc (NUVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NUVB|Nuvation Bio Inc|Price:6.420|Chg%:-0.055 - TradingKey
Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvation Bio Inc. (NUVB) Stock Analysis: A Potential 90% Upside In The Biotech Sector - DirectorsTalk Interviews
Nuvation Bio Inc (NUVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvation Bio to report Q2 2026 results on August 6 - scanx.trade
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential - Investing.com India
Nuvation Bio To Report Second Quarter 2026 Financial Results - TradingView
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Yahoo Finance
Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says - Moomoo
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential By Investing.com - Investing.com South Africa
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case - Sahm
Frontier tech research, news & data - MLQ.ai
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung - Pharmaceutical Executive
symbol__ Stock Quote Price and Forecast - CNN
Nuvation Bio stock jumps on safusidenib trial expansion plans - Investing.com India
Nuvation Bio stock jumps on safusidenib trial expansion plans By Investing.com - Investing.com Nigeria
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
BUZZ-U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio - Bitget
NUVB Stock Slides On Financing As Bullish Analysts Double Down - StocksToTrade
Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data - Yahoo
Nuvation Bio reports 51.9% response rate for safusidenib in Phase 2 glioma study - grafa.com
Why Is Nuvation Bio Stock Gaining Monday? - Benzinga
Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program - Bitget
Nuvation Bio (NUVB) Corporate presentation Summary - Quartr
Nuvation Bio expands safusidenib program with two new studies By Investing.com - Investing.com Nigeria
Nuvation Bio expands safusidenib program with two new studies - Investing.com
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma - Investing News Network
NUVB: IBTROZI's global success and a robust pipeline drive growth in high-value oncology markets - TradingView
Form 4 Nuvation Bio Inc For: 17 July By Investing.com - Investing.com South Africa
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
How Nuvation Bio Manages its Ongoing Clinical Trials - Pharmaceutical Executive
Goodwin Advises On Nuvation Bio’s $287.5 Million Registered Convertible Senior Notes Offering With Capped Call - Mondaq
The Status of Nuvation Bio’s Pipeline - Pharmaceutical Executive
Nuvation Bio’s Global Strategy - Pharmaceutical Executive
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview - Yahoo Finance
Nuvation Bio Inc Azioni (NUVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvation Bio Inc Azioni (NUVB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Markel Stacy | CHIEF PEOPLE OFFICER |
Jun 23 '26 |
Option Exercise |
1.83 |
125,000 |
229,249 |
157,591 |
| Markel Stacy | CHIEF PEOPLE OFFICER |
Jun 23 '26 |
Sale |
6.03 |
125,000 |
753,188 |
32,591 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Option Exercise |
2.93 |
63,000 |
184,590 |
116,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Sale |
6.02 |
63,000 |
379,191 |
53,000 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Option Exercise |
2.17 |
47,668 |
103,440 |
60,341 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Sale |
6.01 |
47,668 |
286,370 |
12,673 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):